Darmiyan, Inc.
 | |
| Private | |
| ISIN | 🆔 |
| Industry | Software AI Medical Technology |
| Founded 📆 | 2015 |
| Founder 👔 | Padideh Kamali-Zare, Thomas Liebmann, Kaveh Vejdani |
| Headquarters 🏙️ | , , US |
Area served 🗺️ | |
Key people | Padideh Kamali-Zare (CEO) |
| Owner | Privately Owned |
| Members | |
Number of employees | |
| 🌐 Website | darmiyan |
| 📇 Address | |
| 📞 telephone | |
Darmiyan develops software used predominantly in the medical industry. It is currently focused on providing fully-automated proprietary software platforms to input human brain MRI, which results in producing maps that detect Alzheimer’s disease up to fifteen years before symptoms.
As a Y Combinator company and a member of the UC Berkeley SkyDeck accelerator program, Darmiyan invented the technology behind presymptomatic diagnosis of neurodegenerative disorders, with precise quantification and localization of microscopic abnormality in the brain, which will generate accurate dynamic maps of distribution kinetics in the brain. This technology assists with diagnosing Alzheimer’s before the onset of symptoms.
For its work, Darmiyan received the Amgen Golden Ticket at MBC BioLabs (formerly called QB3@953), an "award launched by Amgen in 2015 to assist early-stage life sciences companies in their efforts to advance biology and technologies for the benefit of patients suffering from serious illnesses."[1]
Locations[edit]
- Emeryville, California (headquarters)
- San Francisco, California
References[edit]
- ↑ "Amgen And QB3@953 Announce Winners Of The Amgen Golden Ticket". Cision Communications - PR Newswire Association LLC. 11 July 2017.
External links[edit]
- Darmiyan’s software detects early stages of Alzheimer’s
- QB3@953 Unites Life-Science Facility Under New MBC BioLabs Name
This article "Darmiyan Inc (Company)" is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
